Erythroleukoplakia clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Pembrolizumab in Treating Participants with Leukoplakia

    open to eligible people ages 18 years and up

    This phase II pilot trial studies how well pembrolizumab works in treating leukoplakia. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

    Los Angeles, California and other locations

Our lead scientists for Erythroleukoplakia research studies include .

Last updated: